Harmony Q2 net revenue $172.8M (+29% YoY); non-GAAP EPS $1.05 vs $0.76; FY guidance reaffirmed

Harmony Biosciences Holdings, Inc.

2024-Q2 EPS reported $0.87 revenue$327,429,000

Net product revenue $172.8M for Q2 2024, up 29% from $134.2M in Q2 2023.
GAAP net income $11.6M ($0.20 diluted EPS) vs $34.3M ($0.56) prior year; non-GAAP adjusted net income $60.6M ($1.05 diluted EPS) vs $45.9M ($0.76).
Average patients on WAKIX increased sequentially by ~250 to approximately 6,550 for the quarter.
FY 2024 net product revenue guidance reiterated at $700-$720 million.
FDA approved WAKIX for pediatric narcolepsy (EDS) on June 21, 2024; commercial launch began July 1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.